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The diagnosis of brain glioma can challenging, particu-
larly when the masses are very large. While the majority
of gliomas are astrocytomas or oligodendrogliomas,
enough are of other types that awareness of these others
is critical. This course will begin with a review of some
of the distinctive features of common and less common
brain tumours, with particular focus on the distinctions
that make a difference in approach.
Once a tumour is diagnosed and therapy instituted,
clinicians will appreciate it greatly if you interpret the
images with a mind to how they measure therapy
response. This requires an awareness of the treatment
regimen the patient is on, and changes in agents like
steroid dose.
RECIST is applied throughout most of the body, but
recently, the Response Assessment in NeuroOncology
(RANO) criteria were published, to address some of the
specifics of neurooncology [1]. These are still largely
visually based, and some are retrospective, designed for
clinical trials, not well-suited for patient management. If
the patient is on trial, the referring physician may wish
to have RANO-based assessments, but in cases where
they are not on protocol, other styles of reporting are
likely to be more valuable.
RANO is largely focused on conventional anatomic
imaging methods, but new quantitative methods reflect-
ing water diffusion and tumour perfusion appear to
improve response assessment. Diffusion restriction typi-
cally reflects higher cell density seen in viable tumour as
well as higher grade tumour [2]. Changes in apparent
diffusion coefficient (sometimes referred to as functional
diffusion mapping) can be very helpful in understanding
an imaging examination [3]. Higher cerebral blood
volume is also seen in viable tumour and higher grade
tumours. When conventional, diffusion and perfusion all
agree, the confidence in one’s assessment can be high
and some have proposed mathematical combinations to
further improve diagnostic performance [4,5]. However,
they often do not agree, and it is critical to be aware of
the limitations and pitfalls in these methods that might
lead to a contradiction and an error in assessment.
The combination of temozolomide and radiation has
been shown to improve survival but also has a high rate
of pseudoprogression, which is present in 1/3 to 1/2 of
subjects, particularly when the tumour is MGMT methy-
lated [6]. It is important to distinguish pseudoprogression
from true progression so that patients can be maintained
on effective therapy. Patients with true progression are
often switched to anti-angiogenic agents that can drama-
tically reduce enhancement and cerebral blood volume,
suggesting response, when the tumour is still growing
(pseudoresponse). Imaging findings that can help to diag-
nose pseudoresponse will also be discussed. Newer
agents like measles vaccine can also produce imaging
findings that can be confusing and confounding, and
examples will be presented.
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